Immunocore’s flotation in the US has raised $258 million.
The pricing of its initial public offering on the Nasdaq in New York, managed by investment banks Goldman Sachs, JP Morgan and Jefferies, is $158m higher than it expected in January.
The Oxford-based company, which delivers biological therapies that have the potential to transform the lives of people with serious diseases including cancer, has also raised $15m in a concurrent private placement. That takes the investment raised today to £200m.
In January Immunocore revealed a £55m Series C funding round and closing of a £74m senior secured loan facility with Oxford Finance LLC.
The news followed positive Phase 3 trial interim analysis data for its lead programme tebentafusp, which aims to help patients with metastatic uveal melanoma, a form of eye cancer.
The investments are intended to fund a potential commercial launch of tebentafusp.
CEO Bahija Jallal said last month: “This successful financing represents another validating milestone for Immunocore as we continue our pioneering work in the field of soluble, bispecific TCR immunotherapies to treat a broad range of diseases.
“The support of our new and existing investors represents a further endorsement of the potential of our powerful technology platform.
“Following the recent positive Phase 3 data for tebentafusp, we are working to progress this investigational agent through the regulatory process as a potential new treatment to metastatic uveal melanoma patients with a high unmet need.”
Immunocore believes tebentafusp could be the first new therapy for the treatment of metastatic uveal melanoma in 40 years.
Commenting on the IPO, Darragh Lyons, CEO of investor Malin, said: “Immunocore’s IPO is a significant milestone for the company… It expects to have several important clinical milestones during the second-half of 2021 and during 2022.”